Mersana Therapeutics CEO Anna Protopapas' 2022 pay falls 66% to $2.8M
Mersana Therapeutics reports 2022 executive compensation
By ExecPay News
Published: April 28, 2023
Mersana Therapeutics reported fiscal year 2022 executive compensation information on April 28, 2023.
In 2022, five executives at Mersana Therapeutics received on average a compensation package of $1.5M, a 49% decrease compared to previous year.
Average pay of disclosed executives at Mersana Therapeutics
Anna Protopapas, Chief Executive Officer, received $2.8M in total, which decreased by 66% compared to 2021. 48% of Protopapas' compensation, or $1.4M, was in option awards. Protopapas also received $436K in non-equity incentive plan, $605K in salary, $421K in stock awards, as well as $7K in other compensation.
For fiscal year 2022, the median employee pay was $243,051 at Mersana Therapeutics. Therefore, the ratio of Anna Protopapas' pay to the median employee pay was 12 to one.
Arvin Yang, Chief Medical Officer, received a compensation package of $1.5M, which increased by 77% compared to previous year. 38% of the compensation package, or $583K, was in option awards.
Brian DeSchuytner, Chief Financial Officer, earned $1.3M in 2022, a 53% decrease compared to previous year.
Timothy B. Lowinger, Chief Science and Technology Officer, received $1.2M in 2022, which decreases by 62% compared to 2021.
Alejandra Carvajal, Chief Legal Officer, earned $875K in 2022, a 60% decrease compared to previous year.
Related executives
Anna Protopapas
Mersana Therapeutics
Chief Executive Officer
Brian DeSchuytner
Mersana Therapeutics
Chief Financial Officer
Alejandra Carvajal
Mersana Therapeutics
Chief Legal Officer
Timothy Lowinger
Mersana Therapeutics
Senior Vice President, Chief Science and Technology Officer
Arvin Yang
Mersana Therapeutics
Chief Medical Officer
You may also like
Source: SEC filing on April 28, 2023.